Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis

OBJECTIVE: To assess the frequency of cardiovascular and venous thromboembolic events in clinical studies of baricitinib, an oral, selective JAK1 and JAK2 inhibitor approved in more than 50 countries for the treatment of moderately‐to‐severely active rheumatoid arthritis (RA). METHODS: Data were poo...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Arthritis Rheumatol
Main Authors: Taylor, Peter C., Weinblatt, Michael E., Burmester, Gerd R., Rooney, Terence P., Witt, Sarah, Walls, Chad D., Issa, Maher, Salinas, Claudia A., Saifan, Chadi, Zhang, Xin, Cardoso, Anabela, González‐Gay, Miguel A., Takeuchi, Tsutomu
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2019
Assuntos:
Rheumatoid Arthritis
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6618316/
https://ncbi.nlm.nih.gov/pubmed/30663869
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40841
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares